MannKind Corporation (NASDAQ:MNKD) is anticipating the approval of its diabetes treatment drug – Afrezza, by July 15, 2014! FDA’s advisory committee earlier recommended the use of this drug to treat Type1 and Type2 Diabetes. However, the regulatory authority delayed its Prescription Drug User Fee Act or PDUFA review by July 15. MannKind Corporation (NASDAQ:MNKD) weekly performance is 0.57%. On last trading day company shares ended up $10.58. Analysts mean target price for the company is $9.06. MannKind Corporation (NASDAQ:MNKD) distance from 50-day simple moving average is 30.45%.
Ariad Pharmaceuticals (NASDAQ:ARIA) has received a consensus rating of “Hold” from the twenty-three analysts that are presently covering the stock. Three equities research analysts have rated the stock with a sell recommendation, eleven have given a hold recommendation and seven have given a buy recommendation to the company. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares fell -0.23% in last trading session and ended the day on $6.39. ARIA Gross Margin is 79.20% and its return on assets is -66.50%. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) quarterly performance is -15.99%.
Vertex Pharmaceuticals Incorporated (VRTX) announced that a combination therapy of two of its drugs used for treating cystic fibrosis has yielded statistically favorable results in its late-stage clinical trials. Upon approval, it would be marketed to treat cystic fibrosis, a genetic condition that afflicts 30,000 US residents, and about 75,000 people around the world. Vertex Pharmaceuticals Incorporated (NASDAQ:VRT) shares moved up 3.68% in last trading session and was closed at $93.17, while trading in range of $88.27-$93.30. Vertex Pharmaceuticals Incorporated (NASDAQ:VRT) year to date performance is 25.40%.
OHR Pharmaceutical Inc (OHRP) soared today after Vista Partners updated its coverage for the pharmaceuticals company. Vista Partners has increased its twelve-month target price for OHR Pharmaceutical stock from $14 to $31. OHR Pharmaceutical Inc (NASDAQ:OHRP) ended the last trading day at $9.90. Company weekly volatility is calculated as 25.76% and price to cash ratio as 66.81. OHR Pharmaceutical Inc (NASDAQ:OHRP) showed a positive weekly performance of 6.34%.
StemCells, Inc. (Nasdaq:STEM) reported positive interim results from its Phase I/II clinical trial of the Company’s proprietary HuCNS-SC® human neural stem cell platform in dry age-related macular degeneration (AMD) yesterday evening at the 12th annual meeting of the International Society for Stem Cell Research (ISSCR) in Vancouver, Canada. StemCells Inc (NASDAQ:STEM) weekly performance is -2.87%. On last trading day company shares ended up $2.03. Analysts mean target price for the company is $4.00. StemCells Inc (NASDAQ:STEM) distance from 50-day simple moving average is 43.89%.
Leave a Reply